Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fidrisertib - Ipsen

Drug Profile

Fidrisertib - Ipsen

Alternative Names: BLU-782; IPN-60130

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Developer Blueprint Medicines; Ipsen
  • Class Carbamates; Furans; Piperazines; Piperidines; Pyridazines; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrodysplasia ossificans progressiva

Most Recent Events

  • 01 Dec 2021 Phase-II clinical trials in Fibrodysplasia ossificans progressiva (In adolescents, In children, In the elderly, In adults) in Germany, Netherlands, Spain, United Kingdom, USA (PO) after December 2021 (NCT05039515) (EudraCT2020-002858-24)
  • 01 Dec 2021 Phase-II clinical trials in Fibrodysplasia ossificans progressiva (In adults, In the elderly, In adolescents, In children) in Italy, Sweden (PO) (EudraCT2020-002858-24) (NCT05039515)
  • 17 Feb 2021 Phase-II clinical trials in Fibrodysplasia ossificans progressive in USA (PO), prior to February 2021 (Ipsen pipeline, February 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top